ELI LILLY & Co (LLY) stock
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3021% above fair value
$1351.12−31.63 (-2.29%)
Close on Nov 19, 2026Market cap $1.27TP/E 43.9Yield 0.46%
Eli Lilly free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2022 | Sep 30, 2022 | $1.60B | +14.7% |
| Q2 FY2022 | Jun 30, 2022 | $812.30M | -41.9% |
| Q1 FY2022 | Mar 31, 2022 | $2.16B | +52.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.29B | -41.5% |
| Q2 FY2021 | Jun 30, 2021 | $1.39B | +1023.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.40B | +12.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.41B | +74.2% |
| Q2 FY2020 | Jun 30, 2020 | $2.21B | +1957.2% |
| Q1 FY2020 | Mar 31, 2020 | $124.10M | – |
| Q3 FY2019 | Sep 30, 2019 | $1.25B | – |
| Q2 FY2019 | Jun 30, 2019 | $811.20M | – |
| Q1 FY2019 | Mar 31, 2019 | $107.60M | – |
See a number that looks wrong?